Inventor · disambiguated record
Terrill K. Mcclanahan
Also filed as: MCCLANAHAN TERRILL · MCCLANAHAN TERRILL K
24 granted patents·24 pending applications·271 citations·filing 1996–2020
96Inventor score
Top patents by PatentIndex Score
48 records- 0194US7427402B2Method of evaluating inflammatory skin disorders using IL-17 and/or IL-19SCHERING CORP·Filed 2006·Granted Sep 23, 2008·28 cites·12 claims
- 0294US7282204B2Uses of IL-23 agonists and antagonists; related reagentsSCHERING CORP·Filed 2004·Granted Oct 16, 2007·58 cites·11 claims
- 0393US7501247B2Method of treating skin inflammationSCHERING CORP·Filed 2005·Granted Mar 10, 2009·31 cites·7 claims
- 0491US7740848B2Method of treatment of skin inflammationSCHERING CORP·Filed 2008·Granted Jun 22, 2010·15 cites·7 claims
- 0589US6479638B1Antibodies that specifically bind DNAX leukocyte associated immunoglobulin-like receptorSCHERING CORP·Filed 2000·Granted Nov 12, 2002·19 cites·5 claims
- 0688US8426573B2Nucleic acids encoding TNFγPARHAM CHRISTI L·Filed 2012·Granted Apr 23, 2013·12 cites·7 claims
- 0788US8148507B2Nucleic acid encoding TNFx proteinPARHAM CHRISTI L·Filed 2010·Granted Apr 3, 2012·14 cites·7 claims
- 0885US7776540B2Method of treating skin inflammationSCHERING CORP·Filed 2008·Granted Aug 17, 2010·7 cites·6 claims
- 0983US7999078B2Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptorSCHERING CORP·Filed 2008·Granted Aug 16, 2011·2 cites·24 claims
- 1082US8178095B2Method of treating skin inflammationKASTELEIN ROBERT A·Filed 2010·Granted May 15, 2012·7 cites·20 claims
- 1176US8034341B2Methods of inhibiting tumor growth using blocking antibodies to IL-23RSCHERING CORP·Filed 2009·Granted Oct 11, 2011·1 cites·9 claims
- 1275US6274312B1Intracellular regulatory molecules; related reagentsSCHERING CORP·Filed 1997·Granted Aug 14, 2001·32 cites·9 claims
- 1373US6140076AIg superfamily `dlair` receptors expressed in monocytesSCHERING CORP·Filed 1997·Granted Oct 31, 2000·21 cites·61 claims
- 1467US2014141444A1Isolated Mammalian Monocyte Cell Genes; Related ReagentsADEMA GOSSE JAN·Filed 2014·Application pending·0 cites
- 1567US2005059808A1Isolated mammalian monocyte cell genes; related reagentsSCHERING CORP·Filed 2004·Application pending·0 cites
- 1667US2014141445A1Isolated Mammalian Monocyte Cell Genes; Related ReagentsADEMA GOSSE JAN·Filed 2014·Application pending·0 cites
- 1767US2004143858A1Isolated mammalian monocyte cell genes; related reagentsSCHERING CORP·Filed 2004·Application pending·0 cites
- 1865US8030450B2Canine RANKL and methods for preparing and using the sameINTERVET INC·Filed 2008·Granted Oct 4, 2011·0 cites·17 claims
- 1964US8415460B2Methods of making antibodies specific for cysteine-rich soluble protein C23FRANZ-BACON KARIN·Filed 2009·Granted Apr 9, 2013·0 cites·2 claims
- 2064US2013034561A1Isolated mammalian monocyte cell genes; related reagentsMERCK SHARP & DOHME·Filed 2012·Application pending·0 cites
- 2164US2003105303A1Isolated mammalian monocyte cell genes; related reagentsSCHERING CORP·Filed 2002·Application pending·0 cites
- 2263US6503730B1Nucleic acids encoding a cysteine rich proteinSCHERING CORP·Filed 1998·Granted Jan 7, 2003·9 cites·10 claims
- 2362US7560533B2Binding compounds specific for cysteine-rich soluble protein C23SCHERING CORP·Filed 2002·Granted Jul 14, 2009·0 cites·11 claims
- 2462US7482426B2C23 PolypeptidesSCHERING CORP·Filed 2002·Granted Jan 27, 2009·0 cites·7 claims
- 2562US2008057058A1Uses of il-23 agonists and antagonists; related reagentsSCHERING CORP·Filed 2007·Application pending·0 cites
- 2662US2005287582A1Antibodies that specifically bind to FDF03SCHERING CORP·Filed 2005·Application pending·0 cites
- 2762US2013203060A1Mammalian genes; related reagentsMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 2861US2012020990A1Isolated mammalian monocyte cell genes; related reagentsADEMA GOSSE JAN·Filed 2011·Application pending·0 cites
- 2961US2014065147A1Use of Cytokine Expression to Predict Skin Inflammation; Methods of TreatmentMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
- 3058US2005287593A1Use of cytokine expression to predict skin inflammation; methods of treatmentSCHERING CORP·Filed 2005·Application pending·0 cites
- 3157US5858707APurified mammalian nucleobase permeases; nucleic acids; antibodiesSCHERING CORP·Filed 1996·Granted Jan 12, 1999·10 cites·25 claims
- 3256US7462700B2Canine RANKL and methods for preparing and using the sameSCHERING PLOUGH ANIMAL HEALTH·Filed 2003·Granted Dec 9, 2008·0 cites·22 claims
- 3355US2012276105A1Use of cytokine expression to predict skin inflammation; methods of treatmentKASTELEIN ROBERT A·Filed 2012·Application pending·0 cites
- 3455US2007237772A1Tumor association of mdl-1 and methodsSCHERING CORP·Filed 2007·Application pending·0 cites
- 3554US2021317214A1Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancerMERCK SHARP & DOHME·Filed 2019·Application pending·0 cites
- 3653US2012034219A1Uses of il-23 agonists and antagonists; related reagentsOFT MARTIN·Filed 2011·Application pending·0 cites
- 3751US2006099144A1Tumor association of MDL-1 and methodsSCHERING CORP·Filed 2005·Application pending·0 cites
- 3848US9732151B2Biomarkers for TSLP treatmentMERCK SHARP & DOHME·Filed 2012·Granted Aug 15, 2017·0 cites·9 claims
- 3948US2022380854A1ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTSMERCK SHARP & DOHME·Filed 2020·Application pending·0 cites
- 4046US2016312297A1Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 4145US2022112564A1Gene expression based biomarker of tumor response to pd-1 antagonistsLOBODA ANDREY·Filed 2020·Application pending·0 cites
- 4244US6124436APurified mammalian monocyte antigens and related reagentsSCHERING CORP·Filed 1996·Granted Sep 26, 2000·5 cites·22 claims
- 4344US2016312295A1Gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 4444US2016304969A1Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonistsMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 4543US2002111476A1Mammalian genes; related reagentsFiled 2001·Application pending·0 cites
- 4642US11326211B2Blood-based biomarkers of tumor sensitivity to PD-1 antagonistsMERCK SHARP & DOHME·Filed 2016·Granted May 10, 2022·0 cites·18 claims
- 4741US2005214296A1Methods of modulating cytokine activity; related reagentsSCHERING CORP·Filed 2005·Application pending·0 cites
- 4827US11377693B2System and methods for deriving gene signature biomarkers of response to PD-1 antagonistsAYERS MARK D·Filed 2015·Granted Jul 5, 2022·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Terrill K. Mcclanahan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →